|Study Description:||The goal of the Phase I portion of this study is to find the highest tolerable |
dose of the combination of dasatinib and erlotinib hydrochloride that can be
given to patients with advanced solid tumors.
The goal of the Phase II portion of this study is to learn if this combination
is effective when given to patients with non-small cell lung cancer.
The safety of this combination will be studied in both phases.